Neuren Pharmaceuticals (ASX:NEU) has reported highlights from the fourth quarter 2023 earnings announcement and its partner Acadia Pharmaceuticals’ conference call.
Acadia announced fourth-quarter net sales of DAYBUE (trofinetide) in the US of US$87.1 million.
Neuren said this was the second full quarter of sales since launch in April 2024. Net sales for 2023 since April were US$177.2 million. Acadia also provided guidance for full-year net sales in 2024 of between US$370 million and US$420 million.
Neuren said it anticipates royalties of A$12.8 million for the fourth quarter of 2023, up from A$10.4 million for the third quarter and A$26.8 million for the full year 2023. It said it anticipates royalties of between A$61 million and A$70 million for the full year 2024.
DAYBUE is approved by the US FDA for treating Rett syndrome in adult and paediatric patients aged two and over.
Neuren’s second drug candidate, NNZ-2591, is in Phase 2 development for each of Phelan-McDermid syndrome, Angelman syndrome, Pitt-Hopkins syndrome and Prader-Willi syndrome.
